{
    "nctId": "NCT02370277",
    "briefTitle": "Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer",
    "officialTitle": "Changes in Intestinal Microbiota in Association With Chemotherapy Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Change in intestinal microbiota (composition, abundance, and diversity)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed ductal carcinoma in situ or invasive breast cancer (stage I, stage IIA, stage IIB, and stage IIIA breast cancer)\n* A treatment group including surgery followed by standard treatment of adjuvant chemotherapy such as doxorubicin and cyclophosphamide followed by paclitaxel, docetaxel and cyclophosphamide, or a treatment group including neoadjuvant chemotherapy followed by surgery at the Norris or LAC+USC Medical Center\n* Women of child-bearing potential agree to pregnancy test to confirm she is not pregnant\n* Provide informed consent\n\nExclusion Criteria:\n\n* Metastatic, recurrent, synchronous or metachronous breast cancer\n* History of other cancers (other than non-melanoma skin cancer)\n* History of autoimmune celiac or inflammatory bowel disease\n* Past bariatric surgery\n* Current or recent pregnancy or nursing (within past 12 months)\n* Past treatment with chemotherapy\n* Recent use (within past month) of more than 3 days of antibiotics use\n* Current use of probiotic supplements",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}